Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

JPMorgan Upgrades Meta to Overweight, Raises PT to $820 as Muse AI Agent Hits #3 in App Store

by Team Lumida
53 minutes ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan upgraded Meta from neutral to overweight and raised its December 2027 price target from $640 to $820 — implying 25%+ upside — citing Muse's explosive launch traction...

Read more

Off-Grid AI Power Startup TAR Hits $1B Valuation With $120M Round Led by Anthropic Backer Spark Capital

by Team Lumida
58 minutes ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

TAR, an Austin startup building solar-battery-gas modular power systems that let data centers bypass the grid entirely, raised $120M at a $1B valuation led by Spark Capital —...

Read more

OpenAI Ends $1/Year Federal Deal, Moves to 50% Discount Pricing — While Anthropic’s Government Contracts Remain in Legal Limbo

by Team Lumida
60 minutes ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI is replacing its $1/year federal pilot (which gave 3.5 million government workers ChatGPT access and generated $1.4B in claimed savings) with usage-based pricing at a 50% discount...

Read more

Pensions and Endowments Are Pushing Back on Private Equity’s AI Binge — Circular Deals and Hidden Concentration Alarm LPs

by Team Lumida
1 hour ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Major institutional investors including Florida's $307B pension fund and Ontario Teachers' are demanding more transparency from Apollo, Blackstone, and Brookfield on AI exposure scattered across infrastructure, credit, real...

Read more

Anthropic Researcher Quits, Citing Fear That Industry Is Building AI Systems ‘No One Can Control’

by Team Lumida
1 day ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Jacob Coxon, an Anthropic model-training researcher, resigned Tuesday saying he refuses to participate in an industrywide race toward self-improving AI that could spiral out of human control and...

Read more

NSA, FBI, and CISA Formally Accuse DeepSeek, Alibaba, and Four Other Chinese AI Firms of Systematically Stealing US AI Models

by Team Lumida
1 day ago
Why Alibaba’s $2.8 Billion AI Investment Could Shake Up the Market

A joint advisory from the NSA, FBI, and CISA formally accused DeepSeek, Alibaba, Moonshot AI, MiniMax, StepFun, and Z.AI of using distillation techniques 'at an industrial scale' to...

Read more

Google Plans €13 Billion AI Data Center Build in Finland — Its Largest Single European Investment Ever

by Team Lumida
1 day ago
Google’s Bold AI Bet: Transforming Healthcare After Costly Missteps

Alphabet's Google will invest at least €13 billion ($15.1 billion) in Finnish AI infrastructure over two years, building three new data centers in the country's north and expanding...

Read more

Anthropic Walks Away From $6 Billion Decart AI Acquisition Before IPO Filing

by Team Lumida
2 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic completed due diligence on Decart AI — a chip-efficiency startup valued at ~$4 billion — then decided against the $6B acquisition, a rare move that signals discipline...

Read more

AI-Discovered Drug Reverses Biological Aging by Up to 6 Years in Mid-Stage Trial, Nature Biotechnology Study Finds

by Team Lumida
2 days ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Insilico Medicine's rentosertib — an AI-designed lung disease drug — reduced biological age by up to six years in a 42-patient mid-stage trial, per a Nature Biotechnology study,...

Read more

OpenAI’s Chief Scientist Warns ‘No One Is Prepared’ for AI’s Rise, Calls for Voluntary Slowdowns

by Team Lumida
2 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI chief scientist Jakub Pachocki published a stark warning Sunday that AI is advancing faster than humans can understand or control, urging voluntary development slowdowns — even as...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

white and brown house near green grass field under white clouds and blue sky during daytime

Data Center Surge Sparks Land-Use Battle in Atlanta’s Tech Boom

December 28, 2024
Goldman Sachs Urges Investors to Cut Risk: Is a Selloff Looming?

Goldman Sachs Urges Investors to Cut Risk: Is a Selloff Looming?

June 30, 2024
FedEx Shares Mixed Outlook as Tariffs and Weak International Demand Weigh on Growth

FedEx Shares Mixed Outlook as Tariffs and Weak International Demand Weigh on Growth

June 25, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018